Amendments to the Therapeutic Goods Regulations 1990 (Schedule 5, item 6) have been made resulting in compounded GLP-1 RA products no longer being able to be compounded by pharmacists and supplied to patients.
These amendments will apply to all medicines containing GLP-1 RA analogues, regardless of dosage form, compounded on or after 1 October 2024.
We will be hosting a webinar on 14 August 2024 to explain the changes and how these will impact consumers, pharmacists, and doctors.
Information for consumers
The TGA acknowledges the importance of medicines like Ozempic (semaglutide), Mounjaro (tirzepatide) and Trulicity (dutaglutide) for the health and wellbeing of the people who require them, and the need to have a reliable supply in the community.
We encourage patients who have been accessing these compounded products to speak to their GP about alternative treatment and general healthcare plans. While we recognise shortages cause significant anxiety for patients, it is important that the alternative treatments accessed during shortages are safe and of good quality.
The TGA has published information for consumers regarding buying compounded weight-loss medicines, available at What you need to know about compounded weight-loss medicines.
Information for healthcare practitioners
The TGA will continue to actively monitor the supply of Ozempic, Mounjaro and Trulicity and liaise with sponsors of GLP-1 RA's regarding supply status and availability of their medicines.
Up-to-date information about the shortages of GLP-1 RA medicines is available on the following pages:
- About the Ozempic (semaglutide) shortage 2022 and 2023 | Therapeutic Goods Administration (TGA)
- About the Trulicity (dulaglutide) shortage 2022 and 2023 | Therapeutic Goods Administration (TGA)
- Shortage of Mounjaro (tirzepatide) injections | Therapeutic Goods Administration (TGA)
